Summary:
This 24-month treatment, multicenter, double-blind, placebo-controlled, parallel group, Phase 3 study in participants with Early Alzheimer's Disease (EAD) including mild cognitive impairment (MCI) due to AD/Prodromal AD and the early stages of mild AD will be conducted to evaluate the efficacy and safety of E2609.
Qualified Participants Must:
• Be between 50 and 85 years of age
• Have the availability of a study partner
•
Have memory loss
Qualified Participants May Receive:
May be compensated for time and travel.